One of the main challenges in targeting HPRT for cancer therapy is the potential for off-target effects. Since HPRT is also expressed in healthy cells, inhibitors could cause unwanted toxicity. Moreover, compensatory mechanisms in cancer cells could bypass the need for HPRT, reducing the efficacy of such therapies. Understanding the specific context in which HPRT contributes to cancer progression is crucial for developing effective treatments.
